IS8075A - Viðtakaflóki vefjaverndandi frumuboða, mælingar til þess að bera kennsl á vefjaverndandi efnasambönd og notkun þeirra - Google Patents

Viðtakaflóki vefjaverndandi frumuboða, mælingar til þess að bera kennsl á vefjaverndandi efnasambönd og notkun þeirra

Info

Publication number
IS8075A
IS8075A IS8075A IS8075A IS8075A IS 8075 A IS8075 A IS 8075A IS 8075 A IS8075 A IS 8075A IS 8075 A IS8075 A IS 8075A IS 8075 A IS8075 A IS 8075A
Authority
IS
Iceland
Prior art keywords
tissue
tests
receptor cell
protective compounds
identify
Prior art date
Application number
IS8075A
Other languages
English (en)
Inventor
Brines Michael
Cerami Anthony
Nielsen Mette
Ghezzi Pietro
Fiordaliso Fbio
Fratelli Maddalena
Leist Marcel
Sager Thomas
Gerwien Jens
Coleman Thomas
Pedersen Lars
Original Assignee
Kenneth S. Warren Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth S. Warren Institute, Inc. filed Critical Kenneth S. Warren Institute, Inc.
Publication of IS8075A publication Critical patent/IS8075A/is

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
IS8075A 2003-04-25 2005-10-14 Viðtakaflóki vefjaverndandi frumuboða, mælingar til þess að bera kennsl á vefjaverndandi efnasambönd og notkun þeirra IS8075A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46589103P 2003-04-25 2003-04-25
US10/676,694 US7718363B2 (en) 2003-04-25 2003-09-30 Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
PCT/US2004/013099 WO2004096148A2 (en) 2003-04-25 2004-04-26 Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof

Publications (1)

Publication Number Publication Date
IS8075A true IS8075A (is) 2005-10-14

Family

ID=33303293

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8075A IS8075A (is) 2003-04-25 2005-10-14 Viðtakaflóki vefjaverndandi frumuboða, mælingar til þess að bera kennsl á vefjaverndandi efnasambönd og notkun þeirra

Country Status (13)

Country Link
US (2) US7718363B2 (is)
EP (1) EP1622570A4 (is)
JP (1) JP2006524827A (is)
KR (1) KR20050121270A (is)
AU (1) AU2004233985A1 (is)
BR (1) BRPI0409678A (is)
CA (1) CA2523578A1 (is)
EA (1) EA009745B1 (is)
IS (1) IS8075A (is)
MX (1) MXPA05011134A (is)
NO (1) NO20055525L (is)
NZ (1) NZ543192A (is)
WO (1) WO2004096148A2 (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CN102212019B (zh) 2003-03-14 2015-05-27 蔚所番有限公司 支化水溶性聚合物及其缀合物
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US20060216757A1 (en) * 2003-04-25 2006-09-28 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
MXPA05011832A (es) 2003-05-09 2006-02-17 Neose Technologies Inc Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
WO2004109254A2 (en) * 2003-06-06 2004-12-16 Ionwerks Fullerene-based maldi matrices for peptides and proteins
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EA010650B1 (ru) * 2003-09-29 2008-10-30 Уоррен Фармасьютикалз, Инк. Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
CN101378772B (zh) * 2005-08-05 2013-12-04 阿拉伊姆药品公司 组织保护性肽及其用途
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
HUE026591T2 (hu) * 2007-11-29 2016-06-28 Molecular Health Gmbh Szövetvédõ eritropoietin receptor (nepor) és alkalmazási eljárásai
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
PL2245056T4 (pl) 2008-01-22 2016-01-29 Araim Pharmaceuticals Inc Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
WO2010083532A1 (en) * 2009-01-19 2010-07-22 The Research Foundaton Of State University Of New York Fatty acid binding proteins as drug targets for modulation of endocannabinoids
AU2011282245B2 (en) * 2010-07-19 2017-09-28 Otago Innovation Limited Signal biomarkers
JP6307077B2 (ja) * 2012-08-02 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 不活性免疫グロブリンＦｃ領域とのＦｃ融合体としての可溶性ＦｃＲを生産するための方法およびその使用
MX2016000448A (es) * 2013-07-17 2016-05-12 Araim Pharmaceuticals Inc Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
EP3094750A1 (en) * 2014-01-18 2016-11-23 Attagene, Inc. Multiplexing transcription factor reporter protein assay process and system
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
RU2612913C2 (ru) * 2015-05-12 2017-03-13 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" Способ повышения продолжительности жизни моллюсков Abra segmentum в условиях гипоксии на период от 4 до 14 суток
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2022125865A2 (en) * 2020-12-11 2022-06-16 President And Fellows Of Harvard College Novel screening platform to identify immune modulatory agents

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5292654A (en) 1990-12-13 1994-03-08 Whitehead Institute For Biomedical Research Mutant EPO receptor and uses therefor
DE4228839A1 (de) 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren
ATE323771T1 (de) 1993-08-16 2006-05-15 Jong Y Lee Fragment des menschlichen erythropoietinrezeptors und antikörper dagegen
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5763198A (en) 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
EP0793725B1 (en) * 1994-12-22 2005-09-28 Novartis AG Nuclear protein serine/threonine kinases
AUPN780096A0 (en) 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
JP2001501097A (ja) * 1996-09-24 2001-01-30 ケイダス ファーマスーティカル コーポレイション レセプターエフェクターを同定する方法及び組成物
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CZ20013695A3 (cs) 1999-04-13 2002-02-13 Kenneth S. Warren Laboratories Farmaceutický prostředek
DK1325115T3 (en) 2000-06-26 2016-11-21 Zymogenetics Inc CYTOKINRECEPTOR ZCYTOR17
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
NZ537306A (en) 2002-07-01 2008-11-28 Kenneth S Warren Inst Inc Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
US20050176627A1 (en) 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
MXPA05002617A (es) 2002-09-09 2005-09-08 Warren Pharmaceuticals Inc Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20060216757A1 (en) 2003-04-25 2006-09-28 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof
CN1946416A (zh) 2003-05-19 2007-04-11 肯尼思S·沃伦协会有限公司 用于保护、恢复和增强效应细胞、组织和器官具有延迟的治疗窗口的组织保护性细胞因子
WO2005117927A2 (en) 2004-05-20 2005-12-15 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines with an extended therapeutic window
CN1882355A (zh) 2003-09-09 2006-12-20 沃伦药品公司 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素
EA010650B1 (ru) 2003-09-29 2008-10-30 Уоррен Фармасьютикалз, Инк. Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
WO2005084364A2 (en) 2004-03-03 2005-09-15 The Kenneth S. Warren Institue, Inc. Long acting tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
AU2005270092A1 (en) 2004-07-02 2006-02-09 Cerami, Anthony Method of producing fully carbamylated erythropoietin
WO2006014466A2 (en) 2004-07-02 2006-02-09 The Kenneth S. Warren Institute, Inc. Novel carbamylated epo and method for its production
BRPI0513029A (pt) 2004-07-07 2008-04-22 Lundbeck & Co As H método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
JP2008543975A (ja) * 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
US20080045409A1 (en) 2006-08-16 2008-02-21 Buarque De Macedo Pedro M Ceramic catalysts
US8538421B2 (en) * 2008-10-20 2013-09-17 At&T Mobility Ii Llc Management of network technology selection and display in multi-technology wireless environments
US9030606B2 (en) * 2013-03-14 2015-05-12 Gopro, Inc. Wireless camera housing illuminators
US9290938B2 (en) * 2014-04-09 2016-03-22 Wickright, Inc. Construction system for releasing moisture from a hip, valley or gable roof

Also Published As

Publication number Publication date
EA009745B1 (ru) 2008-04-28
NO20055525L (no) 2006-01-16
EP1622570A2 (en) 2006-02-08
AU2004233985A1 (en) 2004-11-11
CA2523578A1 (en) 2004-11-11
EA200501667A1 (ru) 2006-06-30
KR20050121270A (ko) 2005-12-26
BRPI0409678A (pt) 2006-05-02
WO2004096148A3 (en) 2006-03-02
US7718363B2 (en) 2010-05-18
EP1622570A4 (en) 2009-07-08
JP2006524827A (ja) 2006-11-02
MXPA05011134A (es) 2006-05-25
US20040214236A1 (en) 2004-10-28
US20090136519A1 (en) 2009-05-28
NO20055525D0 (no) 2005-11-23
NZ543192A (en) 2008-07-31
WO2004096148A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
IS8075A (is) Viðtakaflóki vefjaverndandi frumuboða, mælingar til þess að bera kennsl á vefjaverndandi efnasambönd og notkun þeirra
IS8434A (is) Verndandi vírnet, verndandi formgerð búin til meðnetinu og notkunin á verndandi vírnetinu við að búa til verndandi formgerð
DK1753406T4 (da) Overtrukket tabletformulering og fremgangsmåde
IS8054A (is) Kannabinóíð viðtaka bindlar og notkun þeirra
IS8032A (is) Kannabinóíð viðtakabindlar og notkun þeirra
DE602004024068D1 (de) Bedingungsanalyseeinrichtung
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
SE0203435L (sv) Blodprovsapparat
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
DE60306039D1 (de) Speicherzelle und Speichervorrichtung
EP1887067A4 (en) FLUORESCENT AND ITS USE
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
DE602004008549D1 (de) Drehbares, tragbares Gerät
DE602004027946D1 (de) Klappbares tragbares endgerät
DE602004007498D1 (de) Testemulationseinrichtung
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
EP1589597A4 (en) Electrochemical device
EP1810357A4 (en) Electrochemical device
EP1629557A4 (en) Polyimide MATRIX ELEKTROLYT
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
UY3454Q (es) Cinta para prueba electroquimica
DE602004016671D1 (de) Testvorrichtung
DK1359458T3 (da) Brillestel og hængselsenhed til anvendelse deri
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra